Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

2pumps1dump Mar. 12 at 9:18 PM

$CPIX

0 · Reply

2pumps1dump Mar. 12 at 9:17 PM

$CPIX https://archive.fast-edgar.com/20260312/ARZZS22CZ22IC2Z2222R22ZBFLSQZZ282Z82/cmb26-0398992025annualrepo.pdf

0 · Reply

BioResearcher Mar. 12 at 8:06 PM

$CPIX The only green stock in my portfolio today :-)

0 · Reply

haha1978 Mar. 12 at 2:32 PM

$CPIX it was 4.1% placebo vs 6.2% control an average of 10% improvement with some outliers by up to 40%.

0 · Reply

haha1978 Mar. 12 at 2:19 PM

$CPIX in general the asprin study was weak for fatty liver it was 6% improvement. Ifetroban is definitely needed for a p2 trial for fatty liver. https://blogs.the-hospitalist.org/content/low-dose-aspirin-reduces-liver-fat-inflammation-markers#:~:text=At%20baseline%2C%2036.3%25%20of%20all,and%20liver%20stiffness%20by%20VCTE.

0 · Reply

haha1978 Mar. 12 at 2:10 PM

$CPIX new study out showing aspirin can reduce fatty liver by 40%. Makes you wonder how much better ifetroban would be if its 10x stronger. They should pursue the fatty liver after DMD.

0 · Reply

BioResearcher Mar. 12 at 1:13 PM

$CPIX Ifetroban and Aspirin have potential to prevent cancer from spreading by acting on TXA2. I just found that The scientists are running a big phase 3 trial using low-dosed Aspirin: "Add-Aspirin" Maybe that is the reason BP are not interested in Ifetroban. because Ifetroban will be against a generic drug. "Add-Aspirin is a large randomised clinical trial, which is taking place in the UK, Republic of Ireland and India. It will recruit 11,000 participants to help find out whether regular aspirin use after treatment for an early stage cancer can prevent the cancer from coming back and preventing deaths."

1 · Reply

haha1978 Mar. 10 at 8:37 PM

$CPIX 50 million market cap. This coukd be the shake before IPF data release. No reason for this far a drop 38%.

1 · Reply

avikiyan11 Mar. 10 at 7:43 PM

$CPIX Is financing in near term causing this weakness?

0 · Reply

ZacksResearch Mar. 10 at 7:19 PM

$CPIX is turning heads — can the Talicia boost keep the momentum going? Q4 revenues jumped 31% and the year-over-year loss narrowed, driven by strong sales of Vibativ, Sancuso, and the newly launched Talicia. See what’s fueling Cumberland’s turnaround here 👉 https://www.zacks.com/stock/news/2881853/cumberland-q4-loss-narrows-yy-as-talicia-launch-boosts-sales?cid=sm-stocktwits-2-2881853-teaser-36880&ADID=SYND_STOCKTWITS_TWEET_2_2881853_TEASER_36880

0 · Reply

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2025 Earnings Call Prepared Remarks Transcript

Mar 3, 2026, 5:00 PM EST - 10 days ago

CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

Feb 25, 2026, 7:00 AM EST - 16 days ago

Joint U.S. Commercialization of RedHill's Talicia® Commences

RDHL

Feb 25, 2026, 7:00 AM EST - 16 days ago

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

Feb 24, 2026, 4:05 PM EST - 17 days ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

Feb 4, 2026, 9:05 AM EST - 5 weeks ago

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

Dec 8, 2025, 9:05 AM EST - 3 months ago

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Nov 4, 2025, 6:06 PM EST - 4 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:00 PM EST - 4 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Oct 28, 2025, 4:05 PM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Oct 20, 2025, 9:05 AM EDT - 5 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

Oct 20, 2025, 9:00 AM EDT - 5 months ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Oct 13, 2025, 9:05 AM EDT - 5 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Oct 1, 2025, 9:05 AM EDT - 5 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

Sep 29, 2025, 9:05 AM EDT - 5 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Aug 6, 2025, 1:52 AM EDT - 7 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 7 months ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 4, 2025, 9:05 AM EDT - 7 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 8 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Jun 23, 2025, 9:05 AM EDT - 9 months ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 10 months ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

May 13, 2025, 4:05 PM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 10, 2025, 4:23 AM EDT - 11 months ago

Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 11 months ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 11 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 1 year ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 7:14 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 18, 2025, 7:30 AM EST - 1 year ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 4, 2025, 1:31 PM EST - 1 year ago

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Feb 4, 2025, 7:30 AM EST - 1 year ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 10, 2024, 12:08 PM EST - 1 year ago

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Nov 9, 2024, 1:17 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 1 year ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 11, 2024, 12:47 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 11, 2024, 11:51 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 2 years ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 10:06 PM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 11, 2023, 8:17 AM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript

2pumps1dump Mar. 12 at 9:18 PM

$CPIX

0 · Reply

2pumps1dump Mar. 12 at 9:17 PM

$CPIX https://archive.fast-edgar.com/20260312/ARZZS22CZ22IC2Z2222R22ZBFLSQZZ282Z82/cmb26-0398992025annualrepo.pdf

0 · Reply

BioResearcher Mar. 12 at 8:06 PM

$CPIX The only green stock in my portfolio today :-)

0 · Reply

haha1978 Mar. 12 at 2:32 PM

$CPIX it was 4.1% placebo vs 6.2% control an average of 10% improvement with some outliers by up to 40%.

0 · Reply

haha1978 Mar. 12 at 2:19 PM

0 · Reply

haha1978 Mar. 12 at 2:10 PM

$CPIX new study out showing aspirin can reduce fatty liver by 40%. Makes you wonder how much better ifetroban would be if its 10x stronger. They should pursue the fatty liver after DMD.

0 · Reply

BioResearcher Mar. 12 at 1:13 PM

1 · Reply

haha1978 Mar. 10 at 8:37 PM

$CPIX 50 million market cap. This coukd be the shake before IPF data release. No reason for this far a drop 38%.

1 · Reply

avikiyan11 Mar. 10 at 7:43 PM

$CPIX Is financing in near term causing this weakness?

0 · Reply

ZacksResearch Mar. 10 at 7:19 PM

0 · Reply

ZacksResearch Mar. 10 at 6:19 PM

$CPIX down 29.5% post-Q4 results — what’s going on? 📉 Despite a 31% quarterly revenue boost driven by demand across several brands and early Talicia sales, rising operating costs and generics competition for Kristalose are weighing on the stock. 🚨 See the full breakdown here 👉 https://www.zacks.com/stock/news/2881853/cumberland-q4-loss-narrows-yy-as-talicia-launch-boosts-sales?cid=sm-stocktwits-2-2881853-body-36881&ADID=SYND_STOCKTWITS_TWEET_2_2881853_BODY_36881

0 · Reply

StocktwitsEarnings Mar. 9 at 10:04 AM

$CPIX Q4 '25 Earnings Results & Recap Cumberland Pharmaceuticals Inc. reported net revenues of $44.5M for 2025, up from $37.9M in 2024, with a net loss of -$2.8M for 2025, an improvement from -$6.4M in 2024.

0 · Reply

BioResearcher Mar. 4 at 11:53 PM

$CPIX another question is why they have not shown us the OLE data? Did it fail in longer term?

2 · Reply

2pumps1dump Mar. 4 at 10:51 PM

$CPIX support for market growth https://www.prnewswire.com/news-releases/h-pylori-infections-market-in-the-6mm-to-observe-stupendous-growth-at-a-cagr-of-9-5-during-the-forecast-period-20262036--delveinsight-302702268.html

0 · Reply

BioResearcher Mar. 4 at 9:30 PM

$CPIX Another thing is they are too vague about the timeline, The CEO said SSC and IPF data will be released this YEAR !!! ??? How about which quarter ? Why give investors such a big span ?

1 · Reply

BioResearcher Mar. 4 at 9:16 PM

$CPIX I think people expected AA on DMD, but now they need to run phase 3, that requires a lot of funding, and it will take another 4 - 5 years. Also cash it lower now.

2 · Reply

jimmy18000 Mar. 4 at 8:22 PM

$CPIX it doesn’t warrant a 17% hair cut after a good earnings report.

0 · Reply

capeeshxz Mar. 4 at 8:16 PM

$CPIX @EvelKing @haha1978 @Timmyyy @BioResearcher agreed! With growing sales, improving balance sheet, strong clinical pipeline - what's not to like? Was market expectings GAAP profitiabiltiy or DMD registerational trial capital need?

0 · Reply

BioResearcher Mar. 4 at 8:11 PM

$CPIX Same profit taking every ER.

0 · Reply

EvelKing Mar. 4 at 7:51 PM

$CPIX I am a bit surprised by the pricing. I thought the report was decent.

0 · Reply

ap20 Mar. 4 at 7:40 PM

$CPIX I’m one click away from having all the fun I can take with this little stock. And then it will go up for the rest of y’all.

0 · Reply

haha1978 Mar. 4 at 6:22 PM

$CPIX last earnings it sold off too. Did management say when IPF or sclerosis data was going to be released? Its been 3 months already.

0 · Reply

Market Cap	46.22M
Revenue (ttm)	44.52M
Net Income (ttm)	-2.84M
EPS (ttm)	N/A
PE Ratio	34.22
Forward PE	N/A
Profit Margin	-6.38%
Debt to Equity Ratio	0.20

Volume	65,300
Avg Vol	188,312
Day's Range	N/A - N/A
Shares Out	14.96M
Stochastic %K	5%
Beta	-0.58
Analysts	Strong Buy
Price Target	$8.50